A white paper titled “Can Global Testing for C. difficile Carriers Help to Prevent Healthcare-associated CDI?” from Luminex discusses the results of two recent studies that show that performing C. difficile testing only in patients with clinically significant diarrhea may be missing an opportunity to prevent CDI transmission from asymptomatic carriers. Download the white paper.
Tagged with: Luminex---
Jan. 14, 2019—Luminex has completed its acquisition of MilliporeSigma’s flow cytometry portfolio for $75 million. The flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis and the Guava portfolio of microcapillary flow cytometry systems. “The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating …
Webinar presenters Margie A. Morgan, PhD, D(ABMM), and Gregory J. Berry, PhD, D(ABMM), discuss the impacts of this past year’s flu season. This webinar will empower you to anticipate the impact of another significant flu season, assess your health care system testing needs; and choose the appropriate tests/algorithm for your lab. This on-demand webinar originally broadcast on August 15, 2018.
August 2017—Luminex received FDA clearance for the Aries Bordetella Assay for direct detection and identification of Bordetella pertussis and Bordetella parapertussis nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis.